Anti-Reg EO Puts Biden-Era NIH ‘Patient Access’ Plan In Crosshairs

By Gabrielle Wanneh / April 14, 2025 at 5:14 PM

New calls by the Trump administration for agencies and industry to target regulations that aren’t dictated by statute puts a controversial Biden-era accessibility plan for products developed with NIH-funded research in the crosshairs, pharmaceutical intellectual property proponents say.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.